503435-59-4 Usage
Chemical structure
The compound has a naphthyridinone core structure with fluoro and fluoro phenyl substituents, and a morpholinyl group.
Stereochemistry
The compound has a stereochemistry of (2S,6R) at the 2,6-dimethyl-4-morpholinyl group.
Fluorination
The compound contains two fluorine atoms, one at the 6-position of the naphthyridinone core and one at the 4-position of the phenyl group.
Amino group
The compound has an amino group attached to the 2-position of the naphthyridinone core.
Phenyl groups
The compound has two phenyl groups, one at the 1-position and the other at the 4-position of the naphthyridinone core.
Pharmacological activities
The compound potentially possesses various pharmacological activities and is of interest in medicinal and chemical research.
Applications
The compound may be used in the development of new drugs and therapies for various diseases and conditions.
Research interest
The compound is of interest to researchers in the fields of medicinal chemistry and drug discovery.
Synthesis
The compound can be synthesized through various chemical reactions and techniques.
Characterization
The compound can be characterized using various analytical techniques, such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry.
Check Digit Verification of cas no
The CAS Registry Mumber 503435-59-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,3,4,3 and 5 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 503435-59:
(8*5)+(7*0)+(6*3)+(5*4)+(4*3)+(3*5)+(2*5)+(1*9)=124
124 % 10 = 4
So 503435-59-4 is a valid CAS Registry Number.
503435-59-4Relevant articles and documents
1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
-
Page/Page column 163-164, (2010/02/05)
The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
